EGRX's free cash flow for Q2 2023 was $-132.00K. For the 2023 fiscal year, EGRX's free cash flow was decreased by $27.63M and operating cash flow was $-126.00K. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Operating Cash Flow	$ -9.27M	$ 50.70M	$ 28.22M	$ 49.50M	$ 55.99M	$ 52.38M
Investing Cash Flow	$ -23.81M	$ -86.83M	$ -5.32M	$ -18.25M	$ -777.00K	$ -133.00K
Financing Cash Flow	$ 11.92M	$ -6.21M	$ -28.39M	$ -37.87M	$ -24.23M	$ -88.12M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 53.31M	$ 55.32M	$ 97.66M	$ 103.16M	$ 109.78M	$ 78.79M
Income Tax Paid Supplemental Data	$ 37.20M	$ 28.41M	$ 10.01M	$ 6.43M	$ 6.67M	$ 2.28M
Interest Paid Supplemental Data	$ 4.06M	$ 1.73M	$ 1.20M	$ 2.22M	$ 2.48M	$ 2.08M
Issuance Of Capital Stock	-	-	-	-	-	-
Issuance Of Debt	$ 11.00M	$ 11.14M	$ -8.00M	$ 110.00M	$ 0.00	$ 0.00
Repayment Of Debt	$ -86.00M	$ -68.86M	$ -8.00M	$ -115.00M	$ -6.00M	$ -3.75M
Free Cash Flow	$ -9.34M	$ 50.52M	$ 22.90M	$ 48.75M	$ 55.21M	$ 52.25M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Eagle Pharmaceuticals Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing